How statins are tested on Step 1

Expect a mechanism question about LDL receptors, a patient with muscle pain and dark urine after adding a drug, or a comparison of lipid-lowering classes.

workspace_premium Why lowering synthesis lowers blood LDL

Statins work mainly by upregulating hepatic LDL receptors, not just by making less cholesterol. That is why they fail in homozygous familial hypercholesterolemia with no functional LDL receptors.

Mechanism

Hepatocytes sense intracellular cholesterol through SREBP-2. When cholesterol falls, SREBP-2 moves to the nucleus and increases transcription of HMG-CoA reductase and the LDL receptor.

HMG-CoAreductaseBlocked bystatins↓Mevalonate↓ HepaticcholesterolSREBP-2Activated↑ LDLreceptorsOnhepatocytes↓ BloodLDLCleared bythe liver
Statin mechanism. Mevalonate is also a precursor of coenzyme Q10 and isoprenoids, which may contribute to myopathy.

Statin intensity

Statin choice is framed by intensity β€” the expected percentage reduction in LDL.

More LDL loweringLow intensity< 30% LDL ↓: simvastatin 10 mg, pravastatin 10–20 mgModerate30–49% ↓: atorvastatin 10–20 mg, rosuvastatin 5–10mgHigh intensityβ‰₯ 50% ↓: atorvastatin 40–80 mg, rosuvastatin 20–40mg
Statin intensity. High-intensity statins are used for clinical ASCVD and LDL β‰₯ 190 mg/dL.
GroupStatin recommendation
Clinical ASCVD (MI, stroke, PAD)High intensity
LDL β‰₯ 190 mg/dLHigh intensity
Diabetes, age 40–75Moderate (high if additional risk)
Age 40–75, 10-year ASCVD risk β‰₯ 7.5%Moderate to high, after shared decision-making

If LDL remains above goal on a maximal statin, add ezetimibe, then a PCSK9 inhibitor.

Statins vs other lipid-lowering drugs

Each class targets a different step of lipoprotein handling.

DrugMechanismMain effectKey adverse effect
StatinsInhibit HMG-CoA reductase↓↓↓ LDLMyopathy, ↑ transaminases
EzetimibeBlocks NPC1L1 intestinal cholesterol absorption↓ LDLDiarrhea, rare ↑ transaminases
PCSK9 inhibitors (evolocumab)Prevent LDL receptor degradation↓↓↓ LDLInjection-site reactions
Bile acid sequestrantsBind bile acids in the gut↓ LDL, ↑ TGGI upset, ↓ absorption of fat-soluble vitamins and drugs
Fibrates (gemfibrozil, fenofibrate)Activate PPAR-Ξ± β†’ ↑ lipoprotein lipase↓↓↓ TGMyopathy (with statins), gallstones
NiacinInhibits lipolysis in adipose tissue↑↑ HDL, ↓ TGFlushing (prostaglandins), hyperglycemia, hyperuricemia
Omega-3 fatty acids↓ Hepatic VLDL production↓ TGFishy taste, AF risk at high dose

Niacin flushing is prevented with aspirin taken beforehand.

Adverse effects and interactions

Muscle toxicity is the signature statin problem; its risk depends on dose and drug levels.

Adverse effectsMyalgia (common, often nocebo)Myopathy with ↑ CKRhabdomyolysis β€” rare, dark urine, AKIElevated transaminasesSlight ↑ risk of type 2 diabetesUsually stopped in pregnancyRaise myopathy riskCYP3A4 inhibitors: clarithromycin,azoles, protease inhibitorsGrapefruit juiceGemfibrozil (blocks statinglucuronidation)HypothyroidismOlder age, CKDHigh-dose simvastatinvs
Myopathy risk. Pravastatin and rosuvastatin are not CYP3A4 substrates, so they are safer with interacting drugs.
functions Worked example β€” the dark urine

A man on simvastatin 40 mg is prescribed clarithromycin for pneumonia. Four days later he has diffuse muscle pain, weakness, and cola-colored urine. CK is 42,000 U/L. Explain.

  1. Simvastatin is metabolized by CYP3A4.
  2. Clarithromycin is a strong CYP3A4 inhibitor, raising simvastatin levels several-fold.
  3. High statin levels cause muscle necrosis; myoglobin in urine gives the dark color and urine dipstick is positive for blood without RBCs.
  4. Myoglobin is toxic to renal tubules.

Answer. Statin-induced rhabdomyolysis from a CYP3A4 interaction. Stop the statin, give aggressive IV fluids, and use azithromycin (not a CYP3A4 inhibitor) instead.